[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 816
6. Geyer JT, López-García MA, Sánchez-Estevez C, Sarrió D, Moreno-Bueno G, Franceschetti I, Palacios J, Oliva E: Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol; 2009 Aug;33(8):1157-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
  • It has been recently suggested that ovarian serous carcinoma follows a dualistic pathway with low-grade carcinomas arising from borderline tumors and high-grade carcinomas originating de novo.
  • Similarly, our group has shown that based on their molecular profile endometrioid borderline tumors could predate low-grade endometrioid ovarian carcinomas (EOC).
  • It is not clearly understood if low-grade EOC is in turn related to high-grade EOC, or if high-grade EOC may also arise de novo.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542870.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Fanghong Li, Szallasi A, Young RH: Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review. Int J Surg Pathol; 2008 Apr;16(2):222-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wolffian tumor of the ovary with a prominent spindle cell component: report of a case with brief discussion of unusual problems in differential diagnosis, and literature review.
  • An 87-year-old woman underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for endometrioid adenocarcinoma.
  • The uterus showed well-differentiated, superficially invasive endometrioid adenocarcinoma arising in a background of atypical complex hyperplasia.
  • Without further therapy, the patient was alive without disease 7 months after surgery.
  • This case demonstrates the heterogeneity of Wolffian tumor of the ovary and shows how crucial sampling is in arriving at the correct diagnosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Fibroma / pathology. Ovarian Neoplasms / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Wolffian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417686.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Stewart CJ, Amanuel B, Grieu F, Carrello A, Iacopetta B: KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion. J Clin Pathol; 2010 Jul;63(7):604-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS mutation and microsatellite instability in endometrial adenocarcinomas showing MELF-type myometrial invasion.
  • BACKGROUND: Some uterine endometrioid adenocarcinomas exhibit a distinctive morphological phenotype characterised by the formation of microcystic, elongated and fragmented (MELF) glands.
  • METHODS: MSI, and KRAS and BRAF mutation status, were assessed in 33 low-grade endometrial adenocarcinomas showing MELF features and the results compared with 33 control cases exhibiting a 'conventional' pattern of myometrial invasion.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Microsatellite Instability. Mutation. Proto-Oncogene Proteins / genetics. ras Proteins / genetics
  • [MeSH-minor] Adult. Aged. Cell Differentiation / genetics. Epithelial-Mesenchymal Transition / genetics. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Proto-Oncogene Proteins B-raf / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591910.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


9. Liu WK, Jiang XY, Zhang ZX: Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma. Onkologie; 2010;33(5):241-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of PSCA, PIWIL1, and TBX2 in endometrial adenocarcinoma.
  • MATERIAL AND METHODS: The expression of PSCA, PIWIL1, and TBX2 was examined using the streptavidin-peroxidase method in 64 endometrial endometrioid adenocarcinoma (EAC) and paired normal endometrium (NE) samples from the Shaanxi Province in China.
  • [MeSH-major] Adenocarcinoma / genetics. Endometrial Neoplasms / genetics. Gene Expression Regulation, Neoplastic / genetics. Membrane Glycoproteins / genetics. Neoplasm Proteins / genetics. Proteins / genetics. T-Box Domain Proteins / genetics
  • [MeSH-minor] Adult. Age Factors. Aged. Antigens, Neoplasm. Argonaute Proteins. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Endometrium / pathology. Female. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Lymphatic Metastasis / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20502058.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Argonaute Proteins; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / PIWIL1 protein, human; 0 / PSCA protein, human; 0 / Proteins; 0 / T-Box Domain Proteins; 0 / TBX1 protein, human
  •  go-up   go-down


10. Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H: Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer; 2008 May 15;112(10):2211-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
  • BACKGROUND: Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared.
  • Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary.
  • RESULTS: Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013).
  • They presented more often with early disease (stage I and II; 50% vs 17%; P < .001), had less ascites, and had better performance status both overall and for stage II and III disease.
  • More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage.
  • Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001).
  • This relation remained for stage II and III disease and for moderately and poorly differentiated tumors.
  • Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone.
  • Independent predictors of survival after PBC were histological type, debulking status, and disease stage.
  • CONCLUSIONS: Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Organoplatinum Compounds / therapeutic use. Prospective Studies. Survival Rate


11. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The frozen section of the mass on the right adnex revealed malign mucinous carcinoma of the ovary.
  • Furthermore, the focal endometrial irregularity at the left uterine cornus turned out to be a well differentiated endometrial carcinoma of the endometrioid type with <1/3 myometrial invasion.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology


12. Wang LX, Zhou CW, Ouyang H: [Value of high-field MR diffusion-weighted MR imaging in the diagnosis of endometrial carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Nov;31(11):849-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of high-field MR diffusion-weighted MR imaging in the diagnosis of endometrial carcinoma].
  • OBJECTIVE: To investigate the usefulness of high-field MR diffusion-weighted imaging (DWI) in the diagnosis of endometrial carcinoma.
  • The conventional pulse sequences included axial SE T1WI, FSE T2WI and fat saturated FSE T2WI, sagittal FSE T2WI, and coronal fat saturated FSE T2WI.
  • Axial DWI was performed in all patients using a SE-EPI sequence with a 1000 s/mm(2) b value.
  • However, no significant difference in ADC was found between highly-differentiated and moderately-differentiated adenocarcinomas.
  • It can be used to differentiate the endometrial carcinoma from either dysplasia or normal endometrium, but is difficult to differentiate highly-differentiated adenocarcinoma from moderately-differentiated one.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Diffusion Magnetic Resonance Imaging / methods. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / surgery. Diagnosis, Differential. Ectodermal Dysplasia / diagnosis. Endometrium. Female. Humans. Middle Aged. Myometrium

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137351.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


13. Chiarelli S, Buriticá C, Litta P, Ciani S, Guarch R, Nogales FF: An immunohistochemical study of morules in endometrioid lesions of the female genital tract: CD10 is a characteristic marker of morular metaplasia. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4251-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of morules in endometrioid lesions of the female genital tract: CD10 is a characteristic marker of morular metaplasia.
  • PURPOSE: To analyze immunohistochemically morules in endometrioid lesions to show that CD10 is a sensitive marker for morular metaplasia.
  • EXPERIMENTAL DESIGN: Immunohistochemical analysis of 53 instances of morular metaplasia comprising 1 cyclic endometrium and 52 endometrioid lesions associated with focal glandular complexity corresponding to 9 polyps, 4 atypical polypoid adenomyomas, 24 complex endometrial hyperplasias (18 with and 6 without atypia), 12 grade 1 endometrioid adenocarcinomas in early clinical stages of both uterus and ovary, and three ovarian adenofibromas.
  • CONCLUSIONS: CD10 staining represents a useful marker of morules in endometrioid neoplasms of the female genital tract, permitting identification of lesions usually associated with an attenuated malignancy.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Neprilysin / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857799.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


1
Advertisement
4. Nofech-Mozes S, Ghorab Z, Ismiil N, Ackerman I, Thomas G, Barbera L, Covens A, Khalifa MA: Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases. Am J Clin Pathol; 2008 Jan;129(1):110-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial endometrioid adenocarcinoma: a pathologic analysis of 827 consecutive cases.
  • We reviewed 827 consecutive cases of pure endometrial endometrioid adenocarcinoma (EEA) treated by hysterectomy to update the distribution of pathologic features.
  • Tumor grade (reported in a 2-tiered system), depth of myometrial invasion, presence of cervical involvement, lymphovascular invasion (LVI), and evidence of extrauterine disease were recorded.The median age at diagnosis was 62 years (range, 30-94 years).
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Endometrial Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / pathology. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Ovarian Neoplasms / secondary. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18089496.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri A, Iida K, Miyazaki K: Functional and clinicopathological analysis of loss of MKK4 expression in endometrial cancer. Oncology; 2010;79(3-4):238-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade endometrioid adenocarcinoma (G2 and G3) (p = 0.024), postmenopausal status (p = 0.018), and patient age (≥ 60) (p = 0.012) were significantly correlated with lower MKK4 expression.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. MAP Kinase Kinase 4 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Blotting, Western. Cell Adhesion. Cell Movement. Cell Proliferation. Down-Regulation. Female. Genes, Tumor Suppressor. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Invasiveness. Prognosis. RNA, Messenger / genetics. RNA, Small Interfering / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2011 S. Karger AG, Basel.
  • (PMID = 21372598.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.1.- / MAP2K4 protein, human; EC 2.7.12.2 / MAP Kinase Kinase 4
  •  go-up   go-down


16. Aida T, Takebayashi Y, Shimizu T, Okamura C, Higasimoto M, Kanzaki A, Nakayama K, Terada K, Sugiyama T, Miyazaki K, Ito K, Takenoshita S, Yaegashi N: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma. Gynecol Oncol; 2005 Apr;97(1):41-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We performed immunohistochemical analysis of ATP7B using a monoclonal antibody against ATP7B in 51 endometrial endometrioid adenocarcinomas.
  • The patients with ATP7B-positive tumors had a worse prognosis than that with ATP7B-negative tumors in overall survival and disease-free survival, respectively (P < 0.01).
  • [MeSH-major] Adenocarcinoma / enzymology. Adenosine Triphosphatases / biosynthesis. Biomarkers, Tumor / biosynthesis. Cation Transport Proteins / biosynthesis. Endometrial Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Antibody Specificity. Disease-Free Survival. Female. Humans. Immunohistochemistry. Middle Aged. Predictive Value of Tests. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790435.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Cation Transport Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.4 / Wilson disease protein
  •  go-up   go-down


17. Watari H, Xiong Y, Hassan MK, Sakuragi N: Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype. Gynecol Oncol; 2009 Jan;112(1):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype.
  • METHODS: We used immunohistochemistry and RT-PCR to examine the expression of Cyr61 in 92 endometrial carcinomas of endometrioid subtype.
  • We correlated the expression of Cyr61 with various clinicopathologic factors in patients with endometrioid adenocarcinoma.
  • RESULTS: Cyr61 expression was high in 21 of 92 cases of endometrioid adenocarcinoma (22.8%).
  • High expression of Cyr61 was related to poor survival of patients with endometrioid adenocarcinoma.
  • Survival of patients with endometrioid adenocarcinoma could be stratified into three groups by combination of Cyr61 expression and positive LNM with an estimated 5-year survival rate of 96.5% for no LNM irrespective of Cyr61 expression (group A), 85.7% for positive LNM with low/moderate expression of Cyr61 (group B), and 0% for positive LNM with high expression of Cyr61 (group C)(p=0.18 for group A vs group B, p=0.008 for group B vs group C, and p<0.0001 for group A vs group C).
  • CONCLUSIONS: Cyr61 is highly expressed in some endometrial cancer of endometrioid subtype.
  • Cyr61 expression and positive LNM were independent prognostic factors for patients with endometrioid adenocarcinoma.
  • Cyr61 might be a new molecular marker to predict the prognosis of patients with endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cysteine-Rich Protein 61 / biosynthesis. Endometrial Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19007976.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CYR61 protein, human; 0 / Cysteine-Rich Protein 61; 0 / RNA, Messenger
  •  go-up   go-down


18. Slater M, Cooper M, Murphy CR: Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochem; 2006;108(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma.
  • In this retrospective and quantitated study on banked tissue we found that, compared to normal uterine epithelial cells, growth hormone (GH) is increased 3.4-fold in endometriosis and 3.8-fold in endometrial adenocarcinoma.
  • Similarly, interleukin-6 (IL-6) is increased 2.4-fold in endometriosis and 4.4-fold in endometrial adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometriosis / metabolism. Human Growth Hormone / metabolism. Interleukin-6 / metabolism

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564564.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-6; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


19. Krepinska E, Kriz JT, Laco J: Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. Eur J Gynaecol Oncol; 2010;31(5):584-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • The prognosis is much better with survival approaching ten years than if the disease was classified as a single organ disease with metastasis.
  • We report a case of unusual co-existence of endometroid adenocarcinoma of the uterus, serous borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061809.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Witek A, Paul-Samojedny M, Stojko R, Seifert B, Mazurek U: Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma. Gynecol Oncol; 2007 Aug;106(2):407-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexpression index of estrogen receptor alpha mRNA isoforms in simple, complex hyperplasia without atypia, complex atypical hyperplasia and adenocarcinoma.
  • To clarify the molecular mechanisms through which malignant changes are activated in endometrium, this study aims to examine the expression profiles of wild-type ER-alpha and their splice variants and to assess the number of coexisting mRNA isoforms of ER-alpha in normal endometrium as well as in endometrial hyperplasia and endometrial endometrioid adenocarcinoma.
  • Endometrial data were classified into four groups: simple hyperplasia (n=24), complex hyperplasia (n=15), atypical hyperplasia (n=11), endometrial endometrioid adenocarcinoma (n=19) (grade 1, grade 2 morphological degree) and proliferative endometrium (n=24) as a control group.
  • We have evaluated the variation in ERs mRNA level between normal endometrium and endometrial hyperplasia and adenocarcinoma.
  • RESULTS: It was found that the number of coexisting mRNA isoforms was significantly higher in adenocarcinoma endometrium than that evaluated for various degrees of hyperplasia endometrium and normal proliferative endometrium (p<0.05, the Kruskal-Wallis test).
  • CONCLUSION: The risk for progression of endometrial hyperplasia to atypical hyperplasia and eventually endometrioid adenocarcinoma may be accompanied by an increase in the number of alternative splicing variants of mRNA ER-alpha.
  • [MeSH-major] Adenocarcinoma / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Estrogen Receptor alpha / biosynthesis. RNA, Messenger / biosynthesis
  • [MeSH-minor] Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Female. Humans. Protein Isoforms. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561234.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


21. Vang R, Vinh TN, Burks RT, Barner R, Kurman RJ, Ronnett BM: Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma. Int J Gynecol Pathol; 2005 Oct;24(4):391-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinfiltrative tubal metaplasia of the endocervix: a potential form of in utero diethylstilbestrol exposure-related adenosis simulating minimal deviation adenocarcinoma.
  • We report three cases of unusual tubal-type endocervical glandular proliferations simulating minimal deviation adenocarcinoma in women with a history of in utero diethylstilbestrol (DES) exposure.
  • The proliferations lacked features of mucinous and tubo-endometrioid types of minimal deviation adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Cervix Uteri / pathology. Diethylstilbestrol / adverse effects. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Mitosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175088.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


22. Zhang SQ, Cai B, Liu L, He YY, Yang YX, Wan XP: Kallikrein 4 overexpression in endometrial carcinoma and upregulation by estrogen via mitogen-activated protein kinase signal pathway. Int J Gynecol Cancer; 2009 Nov;19(8):1377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expression of KLK4 was analyzed in 15 human normal endometrium, 13 hyperplasia endometrium, and 68 endometrioid adenocarcinoma by immunohistochemistry.
  • Immunohistochemical staining revealed that 92.6% (63/68) of endometrial adenocarcinoma, 61.5% (8/13) of hyperplasia endometrium, and 26.7% (4/15) of normal endometrium were positive for KLK4 protein.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Hyperplasia / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Estradiol / pharmacology. Kallikreins / metabolism. Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Adult. Aged. Blotting, Western. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / drug effects. Tumor Cells, Cultured. Up-Regulation

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009893.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 4TI98Z838E / Estradiol; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 4
  •  go-up   go-down


23. Wanapirak C, Srisupundit K, Tongsong T: Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses. Asian Pac J Cancer Prev; 2006 Jul-Sep;7(3):407-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic morphology scores (SMS) for differentiation between benign and malignant adnexal masses.
  • OBJECTIVE: To determine the sensitivity and specificity of a scoring system for distinguishing between benign and malignant adnexal masses and to detect threshold scores for prediction of malignant ovarian tumors.
  • The final diagnosis was based on either pathological or operative findings.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / ultrastructure. Adenocarcinoma, Mucinous / ultrastructure. Adolescent. Adult. Aged. Carcinoma, Endometrioid / ultrastructure. Cross-Sectional Studies. Cystadenoma, Serous / ultrastructure. Diagnosis, Differential. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059332.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


24. Pan XY, Wang B, Che YC, Weng ZP, Dai HY, Peng W: Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int J Gynecol Cancer; 2007 Jan-Feb;17(1):233-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue.
  • To clarify the roles of claudins in endometrial tumorigenesis, we determined levels of protein and messengerRNA (mRNA) expression of claudin-3 and claudin-4 in human endometrial tissue (proliferative phase [PE, n= 25]; secretory phase [SE, n= 25]; simple hyperplasia [SH, n= 20]; complex hyperplasia [CH, n= 12]; atypical hyperplasia [AH, n= 15]; endometrioid adenocarcinoma [EEC, n= 30]) using immunohistochemistry, western blotting, and real-time polymerase chain reaction, respectively.
  • Morphologic changes of tight junctions (TJs) were also observed in normal, hyperplastic, and malignant endometrial tissue.
  • Absence or weak staining for claudin-3 and claudin-4 was observed in PE, SE, SH, and CH, while medium to intense staining was detected in AH and EEC.
  • Transmission electron microscopy analysis indicated morphologic disruptions of TJs may lag behind the increase of claudins expression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17291259.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-3; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger
  •  go-up   go-down


25. Vilos GA, Edris F, Abu-Rafea B, Hollett-Caines J, Ettler HC, Al-Mubarak A: Miscellaneous uterine malignant neoplasms detected during hysteroscopic surgery. J Minim Invasive Gynecol; 2009 May-Jun;16(3):318-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Miscellaneous uterine malignant neoplasms detected during hysteroscopic surgery.
  • STUDY OBJECTIVES: To estimate the incidence of incidental miscellaneous uterine malignant neoplasms other than endometrioid adenocarcinoma detected during routine resectoscopic surgery in women with abnormal uterine bleeding (AUB) and to examine the effect of hysteroscopic surgery on long-term clinical outcome.
  • Of the 7 with malignant disease, one underwent hysteroscopic partial (n = 1) or complete (n = 6) rollerball electrocoagulation or endomyometrial resection.
  • After diagnosis of uterine cancer, the women were counseled about the disease and management in accord with established clinical practice guidelines.
  • MEASUREMENTS AND MAIN RESULTS: Of the 3892 women, 4 had undiagnosed and 3 had suspected miscellaneous uterine malignant neoplasms including 1 endometrial stromal sarcoma, 2 carcinosarcomas, 2 atypical polypoid adenomyomas of the endometrium, 1 minimal deviation adenocarcinoma of the cervix, and 1 smooth-muscle tumor of uncertain malignant potential.
  • CONCLUSION: Resectoscopic surgery in women with miscellaneous uterine malignant lesions not adversely affect 5-year survival and long-term prognosis.
  • [MeSH-major] Hysteroscopy. Metrorrhagia / surgery. Neoplasms, Complex and Mixed / diagnosis. Smooth Muscle Tumor / diagnosis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19423062.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tokunaga H, Akahira J, Suzuki T, Moriya T, Sasano H, Ito K, Yaegashi N: Ovarian epithelial carcinoma with estrogen-producing stroma. Pathol Int; 2007 May;57(5):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant ovarian neoplasms derived from ovarian epithelium that produce estrogen are rare among postmenopausal women.
  • Presented herein is a case of stage Ic(a) endometrioid adenocarcinoma in the right ovary of an 81-year-old woman, who complained of mammary tenderness, pain and atypical genital bleeding.
  • This case indicates that in addition to stromal tumors, such as granulosa cell tumors, theca cell tumors, adenofibroma and so on, malignant epithelial tumors with a functioning stroma should also be considered when evaluating ovarian tumors with estrogen production in the elderly.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estrogens / metabolism. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493177.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estrogens; 4TI98Z838E / Estradiol
  •  go-up   go-down


27. Wang Y, Yang D, Cogdell D, Hu L, Xue F, Broaddus R, Zhang W: Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma. Technol Cancer Res Treat; 2010 Apr;9(2):179-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / genetics. Endometrial Neoplasms / genetics. Gene Dosage


28. Allen D, O'Brien T, Pingle P, Chandra A: Endometrioid adenocarcinoma of the bladder. Histopathology; 2005 Feb;46(2):232-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the bladder.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693899.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


29. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y: Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol; 2007 Jun;105(3):695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overexpression of MUC1 was significantly associated with various progression parameters such as tumor stage, grade, residual disease status and presence of ascites (P<0.05).
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Mucins / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Amino Acid Sequence. Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Mucin-1. Paraffin Embedding


30. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA: Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer; 2006 Jul 1;107(1):90-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome.
  • METHODS: EMP2 immunophenotype, histologic diagnosis, grade, the presence of lymphovascular invasion, disease stage, and clinical follow-up were determined for 99 endometrial cancers.
  • RESULTS: Significant EMP2 expression (EMP2 positive) was observed in 12 of 99 cancers (9 endometrioid [6 International Federation of Gynecology and Obstetrics Grade 3], 1 serous, 1 mixed endometrioid and serous, and 1 mixed endometrioid and clear cell), and weak EMP2 expression was observed in 11 cancers.
  • The median disease-free interval was only 11 months for patients with EMP2-positive tumors and was not reached for patients with EMP2-weak and EMP2-negative tumors.
  • A multivariate analysis of disease-free survival demonstrated independent, negative prognostic significance for EMP2 expression, high stage, and high-risk histologic subtypes.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16736513.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA16042-29; United States / NCI NIH HHS / CA / CA016042; United States / NICHD NIH HHS / HD / HD048540; United States / NCATS NIH HHS / TR / UL1 TR000124; United States / NICHD NIH HHS / HD / HD40376; United States / NCI NIH HHS / CA / T32 CA009120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EMP2 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


31. Zivanovic O, Carter J, Kauff ND, Barakat RR: A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer. Gynecol Oncol; 2009 Dec;115(3):504-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASES: Two young nulliparous women (29 and 23 years, respectively) with grade 1 endometrioid adenocarcinoma were initially treated with conservative fertility-sparing endocrine therapy.


32. Nogales FF, Buritica C, Godoy C: A dislike for endometrioid-like. Histopathology; 2006 Sep;49(3):315-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dislike for endometrioid-like.
  • [MeSH-major] Adenocarcinoma / classification. Lung Neoplasms / classification. Terminology as Topic
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Histopathology. 2005 Aug;47(2):219-20 [16045787.001]
  • (PMID = 16918982.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


33. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD: A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev; 2008 Apr;17(4):921-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox models were used to estimate associations with endometrial cancer, particularly endometrioid adenocarcinomas, the main histologic type (n = 205).
  • Our data showed that insulin levels were positively associated with endometrioid adenocarcinoma [hazard ratio contrasting highest versus lowest quartile (HR(q4-q1)), 2.33; 95% confidence interval (95% CI), 1.13-4.82] among women not using hormone therapy after adjustment for age and estradiol.
  • Free IGF-I was inversely associated with endometrioid adenocarcinoma (HR(q4-q1), 0.53; 95% CI, 0.31-0.90) after adjustment for age, hormone therapy use, and estradiol.
  • Both of these associations were stronger among overweight/obese women, especially the association between insulin and endometrioid adenocarcinoma (HR(q4-q1), 4.30; 95% CI, 1.62-11.43).
  • These data indicate that hyperinsulinemia may represent a risk factor for endometrioid adenocarcinoma that is independent of estradiol.
  • Free IGF-I levels were inversely associated with endometrioid adenocarcinoma, consistent with prior cross-sectional data.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):649-54 [8547832.001]
  • [Cites] Endocrinology. 1995 Jun;136(6):2531-7 [7750475.001]
  • [Cites] Mol Hum Reprod. 1997 Jan;3(1):21-6 [9239705.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2497-502 [9253324.001]
  • [Cites] Control Clin Trials. 1998 Feb;19(1):61-109 [9492970.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jul;179(1):6-12 [9704758.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):76-9 [9888284.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):188-93 [9935198.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Maturitas. 2005 Jun 16;51(2):187-98 [15917160.001]
  • [Cites] Horm Res. 2005;64(1):9-15 [16088202.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 [16702379.001]
  • [Cites] Growth Horm IGF Res. 2006 Apr;16(2):86-92 [16530441.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):255-63 [17062769.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2656-64 [17285578.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):329-37 [18172327.001]
  • [Cites] Diabetes Res Clin Pract. 2000 Mar;47(3):177-84 [10741566.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Sep;24(9):1085-92 [11033975.001]
  • [Cites] Int J Cancer. 2001 Feb 1;91(3):421-30 [11169969.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):736-9 [11267989.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8 [12433712.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1531-43 [12496040.001]
  • [Cites] Oncology. 2003;64(4):341-5 [12759530.001]
  • [Cites] Ann Epidemiol. 2003 Oct;13(9 Suppl):S107-21 [14575943.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1697-704 [14583772.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):262-8 [14639613.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):607-12 [15066926.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):748-52 [15159305.001]
  • [Cites] Growth Horm IGF Res. 2004 Oct;14(5):337-75 [15336229.001]
  • [Cites] Oncology. 2004;67(1):54-9 [15459496.001]
  • [Cites] Crit Rev Clin Lab Sci. 1984;19(4):297-352 [6373142.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Endocr Rev. 1990 Aug;11(3):443-53 [2226350.001]
  • [Cites] Mol Endocrinol. 1987 Jul;1(7):445-50 [2484720.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Dec;79(6):1723-34 [7527408.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18650-5 [9228034.001]
  • (PMID = 18398032.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093881-01; United States / NCI NIH HHS / CA / R01 CA093881; United States / NCI NIH HHS / CA / R01 CA 93881-01; United States / NCI NIH HHS / CA / R01 CA093881-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin-Like Growth Factor Binding Protein 1; 0 / Insulin-Like Growth Factor Binding Protein 3; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ NIHMS278460; NLM/ PMC3090086
  •  go-up   go-down


34. Lindahl B, Persson J, Ranstam J, Willén R: Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma. Anticancer Res; 2010 Sep;30(9):3727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine clear cell carcinoma (UCC) and uterine papillary serous carcinoma (UPSC) are rare entities that differ in clinical behavior from endometrial adenocarcinoma.
  • Compared with endometrioid adenocarcinoma, they more often metastasize early and more commonly in the upper abdomen including the omentum.
  • In stage Ia, 2/46 patients died of their disease and amongst all the stages, 30/109 patients died of their disease.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Cystadenocarcinoma, Serous / mortality. Uterine Neoplasms / mortality
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Humans. Hysterectomy. Neoplasm Staging. Radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944161.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG: Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol; 2010 Apr;18(2):138-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrial carcinomas, particularly of endometrioid type, can invade the myometrium or cervix without eliciting a stromal desmoplastic or inflammatory response and have been referred to as diffusely infiltrating endometrial carcinomas.
  • The neoplasms consisted of 12 endometrioid carcinomas, 1 mixed endometrioid and clear cell carcinoma, and 1 serous carcinoma.
  • Several of the cases were seen in consultation and the pattern of infiltration raised a number of differential diagnoses, both benign and malignant, depending on the site of tumor involvement, including adenomyosis, adenomyoma, primary endocervical glandular lesions, cervical mesonephric remnants, endometriosis or tuboendometrioid metaplasia, and ovarian cortical inclusion cysts.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors / prevention & control. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Stromal Cells / pathology


36. Lee NK, Cheung MK, Shin JY, Husain A, Teng NN, Berek JS, Kapp DS, Osann K, Chan JK: Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol; 2007 Mar;109(3):655-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Younger patients were more likely to be nonwhite (42.4% versus 18.3%, P<.001) and have stage I disease (79.2% versus 75.3%, P<.001), grade 1 lesions (47.6% versus 35.6%, P<.001), and sarcomas (15.9% versus 8.2%, P<.001) compared with their older counterparts.
  • The overall 5-year disease-specific survival for younger patients was significantly better than that of older women (93.2% versus 86.4%, P<.001).
  • On multivariable analysis, younger age, earlier stage, lower grade, nonblack race, endometrioid histology, and surgical treatment remained as significant independent prognostic factors for improved survival.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Papillary / mortality. Uterine Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329517.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Oztürk HB, Vural B, Calışkan E, Solakoğlu S: Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines. J Turk Ger Gynecol Assoc; 2010;11(3):131-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.
  • OBJECTIVE: The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines.
  • MATERIAL AND METHOD: Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24591918.001).
  • [ISSN] 1309-0399
  • [Journal-full-title] Journal of the Turkish German Gynecological Association
  • [ISO-abbreviation] J Turk Ger Gynecol Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC3939219
  • [Keywords] NOTNLM ; Endometrial cancer / apoptosis / cell proliferation / gonadotropin-releasing hormone analogues / octreotide
  •  go-up   go-down


38. Molckovsky A, Vijay SM, Hopman WM, Bryson P, Jeffrey JF, Biagi JJ: Decreased dose density of standard chemotherapy does not compromise survival for ovarian cancer patients. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):8-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cox regression analysis was used to adjust for age and disease stage.
  • In early-stage disease, 5-year overall survival was 74% and 5-year progression-free survival was 68%.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / mortality. Aged. Carboplatin / administration & dosage. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / mortality. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / mortality. Cisplatin / administration & dosage. Cohort Studies. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511802.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Mendivil A, Schuler KM, Gehrig PA: Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. Cancer Control; 2009 Jan;16(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes.
  • BACKGROUND: Understanding the etiology, presentation, evaluation, and management of selected non-endometrioid endometrial adenocarcinomas of the uterine corpus is needed to define optimal treatment regimens.
  • METHODS: The pathology and treatment of selected non-endometrioid endometrial adenocarcinomas of the uterus are reviewed and summarized.
  • RESULTS: The most common non-endometrioid histology is papillary serous (10%), followed by clear cell (2% to 4%), mucinous (0.6% to 5%), and squamous cell (0.1% to 0.5%).
  • Some non-endometrioid endometrial carcinomas behave more aggressively than the endometrioid cancers such that even women with clinical stage I disease often have extrauterine metastasis at the time of surgical evaluation.
  • Therefore, when technically and medically feasible, comprehensive surgical staging is helpful for women with non-endometrioid endometrial cancer histology.
  • In the setting of optimally debulked advanced-stage disease, a combination of radiation and chemotherapy may be indicated.
  • In the setting of recurrent disease or in women with residual disease after surgery, a platinum-based regimen or enrollment in a clinical trial is recommended.
  • Because both histologies are associated with a high rate of recurrence, adjuvant therapy is recommended even in women with early-stage disease.
  • The remaining cell types should be treated similar to endometrioid or other low-grade histologies.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Neoplasms / pathology. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078929.001).
  • [ISSN] 1526-2359
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 51
  •  go-up   go-down


40. El-Ghobashy AA, Shaaban AM, Innes J, Prime W, Herrington CS: Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. Eur J Cancer; 2007 Sep;43(13):2011-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of neoplasia is associated with abnormalities of cell cycle control and apoptosis.
  • A significant increase in p21 and p53 expression occurred from normal cervix (n=11) through endometriosis/tubo-endometrioid metaplasia (TEM) (n=19) and cervical glandular intraepithelial neoplasia (CGIN)/adenocarcinoma in situ (AIS) (n=33) to invasive adenocarcinoma (n=28).
  • p16 showed diffuse strong expression in CGIN/AIS and invasive adenocarcinoma compared with focal expression in some TEM/endometriosis lesions and no expression in normal cervix.
  • Bcl2 was highly expressed in TEM/endometriosis compared with CGIN/AIS and adenocarcinoma. p16 immunostaining discriminated accurately between neoplastic and non-neoplastic cervical lesions, provided that diffuse strong positivity was present.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cervix Uteri / metabolism. Cyclin-Dependent Kinase Inhibitor Proteins / metabolism. Uterine Cervical Neoplasms / metabolism


41. Mechery J, Adeyemi O: Testosterone secreting endometrioid adenocarcinoma of the ovary. J Obstet Gynaecol; 2005 Nov;25(8):822-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testosterone secreting endometrioid adenocarcinoma of the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / secretion. Ovarian Neoplasms / secretion. Testosterone / secretion

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368600.001).
  • [ISSN] 0144-3615
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone
  •  go-up   go-down


42. Yemelyanova A, Ji H, Shih IeM, Wang TL, Wu LS, Ronnett BM: Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol; 2009 Oct;33(10):1504-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
  • Uterine serous carcinomas typically have a characteristic morphology (papillary architecture, high-grade nuclei) and immunoprofile (diffuse/strong p53 expression, loss of hormone receptor expression) that distinguish them from most endometrial endometrioid carcinomas.
  • However, glandular variants of serous carcinoma can simulate Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) grade 2 endometrioid carcinomas, and some serous carcinomas lack p53 expression and retain hormone receptor expression, making classification difficult.
  • P16 expression patterns distinguish endometrioid carcinomas (patchy) from human papillomavirus (HPV)-related endocervical adenocarcinomas (diffuse/strong) but utility for distinction of serous carcinomas from endometrioid carcinomas and endocervical adenocarcinomas has not been evaluated in a large series.
  • Immunohistochemical analysis of p16 expression was performed on 201 uterine and endocervical adenocarcinomas in hysterectomy specimens, including 49 serous carcinomas, 101 endometrial endometrioid carcinomas (44 FIGO grade 1, 40 FIGO grade 2, and 17 FIGO grade 3), and 51 HPV-related endocervical adenocarcinomas.
  • In contrast, endometrial endometrioid carcinomas exhibited less diffuse and less intense expression, with percent of positive tumor cells ranging from 10% to 90% (mean/median: 38%/30%; staining intensity: variable).
  • Similar to serous carcinomas, all endocervical adenocarcinomas exhibited diffuse/moderate-strong p16 expression, with percentage of positive tumor cells ranging from 90% to 100% (mean/median: 94%/90%).
  • P16 can serve as an additional diagnostic marker, used as part of an immunohistochemical panel, including p53 and hormone receptors, for distinction of uterine serous carcinomas from endometrioid carcinomas.
  • Distinction of serous carcinomas from endocervical adenocarcinomas (HPV-related type), both of which share diffuse p16 expression and frequently lack hormone receptor expression, relies on morphology and diffuse/strong p53 expression in the former and detection of HPV in the latter.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Cystadenocarcinoma, Serous / diagnosis. Endometrial Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] DNA Mutational Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Papillomavirus Infections / complications. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Polymerase Chain Reaction. Tumor Suppressor Protein p53 / genetics. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623034.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


43. Burbos N, Giarenis I, Ostrowski J, Lonsdale R, Nieto JJ: Synchronous diagnosis of multiple tumours in a postmenopausal woman. Arch Gynecol Obstet; 2009 Oct;280(4):627-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous diagnosis of multiple tumours in a postmenopausal woman.
  • A CT scan showed a malignant-appearing right ovarian mass with a peritoneal nodule, small amount of free fluid in the pelvis and evidence of a colonic intussusception.
  • Histopathology showed a Grade 3 endometrial adenocarcinoma.
  • Both ovaries were completely replaced by partially necrotic poorly differentiated endometrioid adenocarcinoma.
  • Small deposits of metastatic adenocarcinoma were seen within the omentum.
  • A large polypoid tumour within the right colon was a tubulo-villous adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Colonic Neoplasms / diagnosis. Genital Neoplasms, Female / diagnosis. Liposarcoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19198863.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Zepiridis L, Zafrakas M, Theodoridis TD, Kaplanis K, Dinas KK, Bontis JN: A unique case of palatinate tonsil metastasis from endometrial cancer. Eur J Gynaecol Oncol; 2009;30(2):229-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of a 55-year-old woman presenting with a palatinate tonsil tumour two and half years after primary diagnosis of endometrioid endometrial adenocarcinoma (FIGO Stage IB, G2) and six months after local disease recurrence is presented.
  • Metastatic disease was treated with systemic chemotherapy, but the patient soon succumbed due to rapid disease progression.
  • [MeSH-major] Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Tonsillar Neoplasms / secondary

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480265.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Nur S, Chuang L, Ramaswamy G: Immunohistochemical characterization of cancer antigen in uterine cancers. Int J Gynecol Cancer; 2006 Sep-Oct;16(5):1903-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pattern of cancer antigen (CA-125) expression by immunohistochemistry (IHC) was investigated in malignant and nonneoplastic endometrium in endometrial carcinoma.
  • Ninety cases of primary uterine carcinomas (65 endometrioid [EM] carcinoma, 15 serous papillary [SP] carcinoma, 6 carcinosarcomas [malignant mixed müllerian tumors], and 4 clear cell carcinoma [CC]) and adjacent atrophic and/or hyperplastic endometrium were analyzed by IHC for CA-125 expression.
  • In malignant mixed müllerian tumors (MMMT), the epithelial component stained as above according to the type of epithelial cell differentiation of the neoplastic cells.
  • [MeSH-major] Adenocarcinoma / metabolism. CA-125 Antigen / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Mixed Tumor, Mullerian / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009990.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


46. Xue LY, Zou SM, Zheng S, Xie YQ, Wen P, Liu XY, Lin DM, Lü N: [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Zhonghua Zhong Liu Za Zhi; 2010 Nov;32(11):838-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate and analyze the expression of fascin and CK14 in multiple histological types of cancer and to explore the potential value of the two proteins as markers in diagnosis and differential diagnosis of various cancer types.
  • METHODS: Tissue microarray containing esophageal squamous cell carcinoma (SCC), lung SCC, larynx SCC, uterine cervical SCC, SCC of external genital organs, lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, heptocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating ductal carcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, 30 cases each, as well as corresponding normal controls was constructed.
  • In lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma and renal clear cell carcinoma, the positive rates were 38.0%, 23.3%, 14.3%, 10.3%, 73.3%, 13.3%, 6.7%, 60.0%, 66.7% and 10.0%, respectively.
  • It was weak and focal in lung adenocarcinoma, gastric adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, pancreatic ductal adenocarcinoma, breast infiltrating dutal adenocarcinoma, thyroid papillary carcinoma, uterine endometrioid adenocarcinoma, ovarian serous adenocarcinoma, and renal clear cell carcinoma, with a positive rate of 13.3%, 13.3%, 20.7%, 41.4%, 46.7%, 6.7%, 40.0%, 13.3%, 20.0% and 6.7%, respectively.
  • Combination of fascin and CK14 should be a valuable marker in diagnosis and differential diagnosis of carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Keratin-14 / metabolism. Laryngeal Neoplasms / metabolism. Microfilament Proteins / metabolism
  • [MeSH-minor] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Male. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223690.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


47. Oe S, Hasegawa K, Nagase S, Kato R, Torii Y, Udagawa Y: Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma. Int J Gynecol Pathol; 2010 Sep;29(5):405-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of podoplanin in epithelial ovarian carcinomas and its potential as a marker for clear cell adenocarcinoma.
  • Podoplanin is a 43-kd mucin-type transmembrane glycoprotein that is a candidate marker for the pathologic diagnosis of mesothelioma and lymphatic endothelial cells and lymphangiogenesis.
  • Immunohistochemistry was performed on the paraffin-embedded tissues from 78 patients with epithelial ovarian carcinomas consisting of serous adenocarcinoma (SA), endometrioid adenocarcinoma (EM), mucinous adenocarcinoma (MA), and clear cell adenocarcinoma (CCC) cases.
  • Podoplanin might have utility as a marker for CCC in pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / analysis. Membrane Glycoproteins / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736762.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Glycoproteins; 0 / PDPN protein, human
  •  go-up   go-down


48. Takao M, Okamoto A, Nikaido T, Urashima M, Takakura S, Saito M, Saito M, Okamoto S, Takikawa O, Sasaki H, Yasuda M, Ochiai K, Tanaka T: Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer. Oncol Rep; 2007 Jun;17(6):1333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously reported that indoleamine-2,3-dioxygenase (IDO) is associated with paclitaxel resistance and that IDO serves as a marker of poor prognosis in ovarian serous adenocarcinomas (SA).
  • Expression of IDO protein was analyzed by immunohistochemistry for a total of 122 ovarian cancers including 40 SA, 67 clear cell adenocarcinomas (CCA), and 15 endometrioid adenocarcinomas (EA) with informed consent.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487387.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase
  •  go-up   go-down


49. Gassler N, Yang SH, Keith M, Helmke BM, Schirmacher P, Obermüller N: Expression of acyl-CoA synthetase 5 in human endometrium and in endometrioid adenocarcinomas. Histopathology; 2005 Nov;47(5):501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of acyl-CoA synthetase 5 in human endometrium and in endometrioid adenocarcinomas.
  • The aim of the present study was to characterize expression and localization of ACS5 in the normal human endometrium and in endometrioid adenocarcinomas.
  • Notably, in endometrioid adenocarcinomas, the ACS5 molecule was found abundantly in well-differentiated tumours, but not in poorly differentiated adenocarcinomas.
  • With regard to its value for histopathological diagnosis, immunohistochemical characterization of endometrioid adenocarcinomas shows that a decrease in ACS5 expression correlates with tumour dedifferentiation.
  • [MeSH-major] Carcinoma, Endometrioid / enzymology. Coenzyme A Ligases / biosynthesis. Endometrial Neoplasms / enzymology. Endometrium / enzymology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16241998.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 6.2.1.- / Coenzyme A Ligases; EC 6.2.1.- / acyl CoA synthetase 5
  •  go-up   go-down


50. Cheng L, Xu JW, Teng XD: [Histologic variants of prostate cancer]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):495-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinosarcoma / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Acinar Cell / pathology. Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / pathology. Carcinoma, Small Cell / pathology. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781207.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


51. Horrée N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP: Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol; 2008 Jan;61(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To explore the expression of cell cycle proteins in normal, premalignant and malignant endometrial lesions representing the morphologically well defined stepwise model of human endometrial carcinogenesis METHODS: Observational study.
  • Paraffin-embedded specimens from inactive endometrium (n = 16), endometrial hyperplasia (n = 23) and endometrioid endometrial carcinoma (n = 39) were stained immunohistochemically for cyclin A, cyclin B1, cyclin D1, cyclin E, cdk2, p16, p21, p27, p53 and Ki67(MIB-1)).
  • CONCLUSION: During (endometrioid) endometrial carcinogenesis, there is increasing proliferation paralleled by progressive derailment of cyclin B1, cyclin D1, cyclin E, p16, p21, p27, p53, and cdk2, indicating the importance of these cell cycle regulators in endometrial carcinogenesis.
  • [MeSH-major] Cell Cycle Proteins / metabolism. Cell Transformation, Neoplastic / metabolism. Endometrial Neoplasms / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cell Proliferation. Disease Progression. Endometrium / metabolism. Endometrium / pathology. Female. Humans. Hyperplasia / metabolism. Hyperplasia / pathology. Middle Aged. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483252.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


52. Qian B, Ke PQ, Wang L, Liu WJ, Li MX: [Expression and methylation of adenomatous polyposis coli gene in endometrioid adenocarcinoma]. Ai Zheng; 2008 Jun;27(6):585-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and methylation of adenomatous polyposis coli gene in endometrioid adenocarcinoma].
  • BACKGROUND & OBJECTIVE: Endometrial carcinoma is a common malignant tumor of female reproductive system, with an increasing incidence in China.
  • Adenomatous polyposis coli (APC) gene, a tumor suppressor gene, is expressed in many tissues, and has a certain relationship with ovarian cancer.
  • This study was to observe the expression and DNA methylation of APC gene in endometrioid adenocarcinoma, and explore its correlations to the occurrence and development of this disease.
  • METHODS: The methylation, mRNA and protein expression of APC gene were detected by methylation-specific polymerase chain reaction (PCR), reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry in 30 specimens of normal proliferative endometrium, 30 specimens of atypical hyperplastic endometrium and 60 specimens of endometrioid adenocarcinoma.
  • RESULTS: The methylation rate of APC gene was significantly higher, the positive rates of APC mRNA and protein were significantly lower in endometrioid adenocarcinoma than in atypical hyperplastic endometrium and normal proliferative endometrium (65.0% vs. 33.3% and 23.3%, 33.3% vs. 63.3% and 73.3%, 30.0% vs. 50.0% and 66.7%,P<0.05).
  • CONCLUSION: The expression and DNA methylation of APC gene are certainly related with the occurrence and development of endometrioid adenocarcinoma.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / genetics. Carcinoma, Endometrioid / genetics. DNA Methylation. Endometrial Neoplasms / genetics

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570730.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / RNA, Messenger
  •  go-up   go-down


53. Mylonas I: Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. Oncol Rep; 2010 Aug;24(2):385-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas.
  • The significance of the relative expression of both ER subtypes in endometrial adenocarcinomas remains to be clarified and the usefulness of the determination of the receptor status in endometrial cancer patients is still controversially discussed.
  • Therefore, the aims of this study were the evaluation of the expression patterns of ER-alpha and ER-beta with the characterization of the prognostic significance in uterine endometrioid adenocarcinomas.
  • Pathological and surgical records of 214 patients who were diagnosed with an endometrioid adenocarcinoma without other histological types (including mucinous, mixed, squamous or villoglandular differentiation) were reviewed for both estrogen receptors.
  • The expression of both estrogen receptors was demonstrated in malignant endometrioid adenocarcinomas.
  • However, ER-alpha and ER-beta were not independent factors with survival in endometrial adenocarcinoma patients.
  • Therefore, the analysis of both estrogen receptors might be used as a marker to identify high-risk patients only in a subset of patients with endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Estrogen Receptor alpha / genetics. Estrogen Receptor alpha / metabolism. Estrogen Receptor alpha / physiology. Estrogen Receptor beta / genetics. Estrogen Receptor beta / metabolism. Estrogen Receptor beta / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596625.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta
  •  go-up   go-down


54. Abu J, Brown L, Ireland D: Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman. Int J Gynecol Cancer; 2006 May-Jun;16(3):1445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.
  • Her main presentation was irregular vaginal bleeding, which is a common finding in women using this form of contraception.
  • [MeSH-major] Carcinoma, Endometrioid / chemically induced. Endometrial Neoplasms / chemically induced. Intrauterine Devices, Medicated / adverse effects. Levonorgestrel / adverse effects

  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803545.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


55. Brown AK, Gillis S, Deuel C, Angel C, Glantz C, Dubeshter B: Abnormal cervical cytology: a risk factor for endometrial cancer recurrence. Int J Gynecol Cancer; 2005 May-Jun;15(3):517-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For endometrioid adenocarcinoma, abnormal cervical cytology occurred in 61% and 7% recurred, while with high-risk histologies, 84% had abnormal cervical cytology and 19% recurred (P < 0.05).
  • [MeSH-major] Carcinoma / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Retrospective Studies. Risk Factors


56. Mylonas I, Makovitzky J, Hoeing A, Richter DU, Vogl J, Schulze S, Jeschke U, Briese V, Friese K: Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue. Acta Histochem; 2006;108(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin subunits beta-A (-betaA) and beta-B (-betaB) are differentially localised in normal, hyperplastic and malignant human endometrial tissue.
  • The aims of this study were to determine the frequency and distribution of INH beta (betaA and betaB) subunits in normal, hyperplastic and malignant human endometrium.
  • Endometrial tissue was obtained from normal, hyperplastic (simple, complex and atypical) and endometrioid adenocarcinoma (EC) and INH-alpha, -betaA and -betaB were labelled using immunohistochemistry and immunofluorescence.
  • A strong colocalisation of inhibin-alpha and -betaA could be demonstrated in malignant endometrial tissue, suggesting the production of inhibin A within the tumour.
  • Additionally, only limited colocalisation of inhibin-betaB with -alpha subunit could be observed, suggesting the synthesis of activin B rather than inhibin B in malignant endometrium.
  • In conclusion, INH-betaA and -betaB were labelled in normal, hyperplastic and malignant endometrium.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16423381.001).
  • [ISSN] 0065-1281
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / inhibin beta A subunit; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


57. Panggid K, Cheewakriangkrai C, Khunamornpong S, Siriaunkgul S: Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res; 2010 Oct;36(5):1044-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
  • AIM: To evaluate the clinicopathological factors associated with recurrence of disease in non-obese women with endometrial endometrioid adenocarcinoma.
  • METHODS: Medical records of the 138 patients who had newly diagnosed endometrial endometrioid adenocarcinoma with body mass index (BMI) <25 and underwent a complete staging surgery between 1999 and 2007 were reviewed.
  • The presence of LVSI, poor histological grade, and advanced stage were found significantly in patients who had disease recurrences (P = 0.026, P < 0.001, and P = 0.015, respectively).
  • CONCLUSION: LVSI, poor histological grade, and advanced stage were associated with disease recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Body Mass Index. Chi-Square Distribution. Disease Progression. Female. Humans. Hysterectomy. Kaplan-Meier Estimate. Medical Records. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21058438.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


58. Yasunaga M, Ohishi Y, Oda Y, Misumi M, Iwasa A, Kurihara S, Nishimura I, Okuma E, Kobayashi H, Wake N, Tsuneyoshi M: Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol; 2009 Jul;40(7):965-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
  • The purpose of this study is to substantiate the concept that mullerian mucinous borderline tumor is histogenetically closer to serous borderline tumor or low-grade endometrioid tumor than to gastrointestinal mucinous borderline tumor by directly comparing their immunophenotype.
  • A total of 80 cases of low-grade ovarian tumors composed of 20 mullerian mucinous borderline tumors, 20 gastrointestinal mucinous borderline tumors, 20 serous borderline tumors, and 20 low-grade endometrioid tumors were immunohistochemically evaluated for the expression of estrogen receptor, progesterone receptor, vimentin, WT-1, beta-catenin, and PTEN.
  • Almost all cases of mullerian mucinous borderline tumor, serous borderline tumor, and low-grade endometrioid tumor showed diffuse and strong nuclear expression of estrogen receptor and progesterone receptor.
  • In addition, about half of the mullerian mucinous borderline tumor, serous borderline tumor, and low-grade endometrioid tumor cases showed focal but strong vimentin cytoplasmic expression.
  • WT-1 nuclear expression was observed in most serous borderline tumors and only 15% of low-grade endometrioid tumor, but mullerian and gastrointestinal mucinous borderline tumor cases were completely negative. beta-Catenin nuclear expression was significantly more frequent in low-grade endometrioid tumor than in mullerian mucinous borderline tumor, gastrointestinal mucinous borderline tumor, or serous borderline tumor.
  • PTEN expression was significantly lower in low-grade endometrioid tumor than in mullerian mucinous borderline tumor, gastrointestinal mucinous borderline tumor, and serous borderline tumor.
  • Multiple comparisons of quantitative immunoreactivities of estrogen receptor, progesterone receptor, and vimentin revealed that the gastrointestinal mucinous borderline tumor expression profiles were significantly different from those of mullerian mucinous borderline tumors, serous borderline tumors, and low-grade endometrioid tumors.
  • The immunohistochemical expression profiles of estrogen receptor, progesterone receptor, and vimentin substantiate the concept that the histogenesis of mullerian mucinous borderline tumor is closer to those of serous borderline tumor and low-grade endometrioid tumor than to that of gastrointestinal mucinous borderline tumor.
  • However, aberrant beta-catenin and PTEN protein expression, both of which are known to contribute to the tumorigenesis of low-grade endometrioid tumor, appeared to be less important for the tumorigenesis of mullerian mucinous borderline tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Genital Neoplasms, Female / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2010 Jan;41(1):151; author reply 151-2 [19854468.001]
  • (PMID = 19269675.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin; 0 / WT1 Proteins; 0 / beta Catenin; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


59. Galgano MT, Conaway M, Spencer AM, Paschal BM, Frierson HF Jr: PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Hum Pathol; 2009 Oct;40(10):1434-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All serous ovarian and endometrial endometrioid adenocarcinomas and mesotheliomas were immunoreactive for PRK1.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):40-6 [10728592.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):220-5 [18374401.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):908-11 [11221880.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):879-85 [11953818.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000 [12096084.001]
  • [Cites] EMBO J. 2003 Jan 15;22(2):270-80 [12514133.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] EMBO J. 2004 Aug 18;23(16):3303-13 [15282551.001]
  • [Cites] Int J Cancer. 1995 Aug 22;64(4):280-5 [7657393.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Obstet Gynecol. 1996 Oct;88(4 Pt 1):554-9 [8841217.001]
  • [Cites] Nat Biotechnol. 1997 Dec;15(13):1359-67 [9415887.001]
  • [Cites] Biochem J. 1998 Jun 1;332 ( Pt 2):281-92 [9601053.001]
  • [Cites] Nat Biotechnol. 1996 Dec;14(13):1675-80 [9634850.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):26-34 [15790433.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):988-1004 [16341064.001]
  • [Cites] Curr Opin Oncol. 2006 Jan;18(1):77-82 [16357568.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5314-21 [17875760.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):864-71 [17617741.001]
  • [Cites] Nat Cell Biol. 2008 Jan;10(1):53-60 [18066052.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • (PMID = 19427017.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104106-049003; United States / NCI NIH HHS / CA / P01 CA104106-04; United States / NCI NIH HHS / CA / P01 CA104106-049003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.1.- / protein kinase N; EC 2.7.11.13 / Protein Kinase C
  • [Other-IDs] NLM/ NIHMS98041; NLM/ PMC2744839
  •  go-up   go-down


60. Nofech-Mozes S, Khalifa MM, Ismiil N, Dubé V, Saad RS, Sun P, Seth A, Ghorab Z: Detection of HPV-DNA by a PCR-based method in formalin-fixed, paraffin-embedded tissue from rare endocervical carcinoma types. Appl Immunohistochem Mol Morphol; 2010 Jan;18(1):80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-risk human papilloma virus (HPV) seems to play a role in the pathogenesis of cervical squamous neoplasia and adenocarcinomas of the mucinous and endometrioid cell types.
  • Cervical serous, clear cell, and small cell carcinomas differ from the conventional endocervical adenocarcinoma in their clinical characteristics.
  • Our report documents HPV status in a series of archival unusual types of adenocarcinoma of the uterine cervix.
  • Despite their unique clinical setting and morphologic appearance, the majority of these tumors likely share a common HPV-mediated carcinogenic pathway.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19625948.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Fixatives; 0 / Reagent Kits, Diagnostic; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


61. Chen CY, Wu YC, Yen MS, Hung JH, Yuan CC, Chao KC: The power Doppler velocity index, pulsatility index, and resistive index can assist in making a differential diagnosis of primary ovarian carcinoma and Krukenberg tumors: a preliminary study. J Ultrasound Med; 2007 Jul;26(7):921-6; quiz 927-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The power Doppler velocity index, pulsatility index, and resistive index can assist in making a differential diagnosis of primary ovarian carcinoma and Krukenberg tumors: a preliminary study.
  • METHODS: Fifty women with ovarian disease were preoperatively examined with transvaginal power Doppler sonography.
  • [MeSH-minor] Adenocarcinoma, Mucinous / physiopathology. Adenocarcinoma, Mucinous / ultrasonography. Adult. Aged. Blood Flow Velocity / physiology. Carcinoma, Endometrioid / physiopathology. Carcinoma, Endometrioid / ultrasonography. Cystadenocarcinoma, Papillary / physiopathology. Cystadenocarcinoma, Papillary / ultrasonography. Cystadenocarcinoma, Serous / physiopathology. Cystadenocarcinoma, Serous / ultrasonography. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasms, Germ Cell and Embryonal / physiopathology. Neoplasms, Germ Cell and Embryonal / ultrasonography. Prospective Studies. Regional Blood Flow / physiology. Sex Cord-Gonadal Stromal Tumors / physiopathology. Sex Cord-Gonadal Stromal Tumors / ultrasonography. Ultrasonography, Doppler, Color. Ultrasonography, Doppler, Pulsed


62. Ghezzi F, Cromi A, Bergamini V, Uccella S, Beretta P, Franchi M, Bolis P: Laparoscopic-assisted vaginal hysterectomy versus total laparoscopic hysterectomy for the management of endometrial cancer: a randomized clinical trial. J Minim Invasive Gynecol; 2006 Mar-Apr;13(2):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Within a median follow-up period of 10 months (range 3-17 months), 2 patients in the LAVH group developed recurrent disease.
  • [MeSH-minor] Adenocarcinoma, Papillary / mortality. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Aged. Carcinoma, Endometrioid / mortality. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Laparoscopes. Lymph Node Excision / methods. Middle Aged. Neoplasm Staging. Pain, Postoperative / diagnosis. Pain, Postoperative / epidemiology. Probability. Risk Assessment. Statistics, Nonparametric. Survival Rate

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527713.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


63. Giatromanolaki A, Koukourakis MI, Turley H, Sivridis E, Harris AL, Gatter KC, Tumour and Angiogenesis Research Group: Phosphorylated KDR expression in endometrial cancer cells relates to HIF1alpha/VEGF pathway and unfavourable prognosis. Mod Pathol; 2006 May;19(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vascular endothelial growth factor (VEGF) is a potent angiogenic factor for many malignant neoplasms exerting its function through activation of specific membrane receptors, that is, KDR/flk-1, residing in endothelial cells.
  • Using a novel monoclonal antibody, recognizing the activated (phosphorylated) form of the KDR receptor (pKDR), we assessed the expression of pKDR in normal and malignant endometrium.
  • Approximately, one-third of the 70 stage I endometrioid adenocarcinomas analysed exhibited an intense cytoplasmic and nuclear pKDR expression in both cancer cells and peritumoral vessels.
  • It is concluded that the VEGF/KDR pathway is activated in both normally cycling and malignant endometrium, suggestive of an important role in the biology of this tissue.
  • The unfavourable prognosis that VEGF confers to endometrial adenocarcinomas could be attributed to its angiogenic activity, but also to a direct effect on cancer cells through an autocrine VEGF/KDR loop.

  • Genetic Alliance. consumer health - Endometrial cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16557278.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Phosphoproteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


64. Singh P, Oehler MK: Hormone replacement after gynaecological cancer. Maturitas; 2010 Mar;65(3):190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main concerns are the potential stimulation of residual cancer and the induction of new hormone-dependent disease.
  • Furthermore, current scientific evidence does not show HRT to adversely affect the outcome in patients after treatment for hormone sensitive cancers like early stage endometrioid adenocarcinomas of the endometrium.
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local. Neoplasms / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018467.001).
  • [ISSN] 1873-4111
  • [Journal-full-title] Maturitas
  • [ISO-abbreviation] Maturitas
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 69
  •  go-up   go-down


65. Hwang JH, Lee JK, Lee NW, Lee KW: Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies. J Reprod Med; 2010 Jan-Feb;55(1-2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of an endometrial tumor that was a combination of an SCC and endometrioid adenocarcinoma with squamous components and that penetrated half of the thickness of the uterine wall.
  • CONCLUSION: Immunohistochemical analyses are helpful in diagnosing and differentiating primary SCC of the endometrium from benign and malignant diseases of the endometrium.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337215.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Synaptophysin
  •  go-up   go-down


66. Mourits MJ, Bijen CB, Arts HJ, ter Brugge HG, van der Sijde R, Paulsen L, Wijma J, Bongers MY, Post WJ, van der Zee AG, de Bock GH: Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol; 2010 Aug;11(8):763-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 283 patients with stage I endometrioid adenocarcinoma or complex atypical hyperplasia were randomly allocated (2:1) to the intervention group (TLH, n=187) or control group (TAH, n=96).
  • [MeSH-major] Carcinoma, Endometrioid / surgery. Endometrial Hyperplasia / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods. Laparoscopy / adverse effects. Laparotomy / adverse effects. Ovariectomy / methods

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Nat Rev Clin Oncol. 2010 Oct;7(10):550 [20922828.001]
  • [CommentIn] Lancet Oncol. 2010 Aug;11(8):707-8 [20638900.001]
  • (PMID = 20638901.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


67. Vlahos NF, Kalampokas T, Fotiou S: Endometriosis and ovarian cancer: a review. Gynecol Endocrinol; 2010 Mar;26(3):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometrioid and clear-cell are the most frequent types of ovarian cancer associated with endometriosis.
  • CONCLUSION: There is evidence to support that endometriosis (by definition a benign process), could simultaneously have the potential for malignant transformation.
  • More studies are needed to establish risk factors that may lead to malignant transformation of this condition and to identify predisposed individuals who may require closer surveillance.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Endometriosis. Ovarian Neoplasms

  • Genetic Alliance. consumer health - Endometriosis.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19718562.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


68. Titford ME, Horenstein MG: Histomorphologic assessment of formalin substitute fixatives for diagnostic surgical pathology. Arch Pathol Lab Med; 2005 Apr;129(4):502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Four experienced board-certified surgical pathologists examined 7 specimens (hepatocellular carcinoma, ovarian sex cord/stromal tumor, myxoid liposarcoma, uterine endometrioid adenocarcinoma, splenic follicular hyperplasia, infiltrating mammary carcinoma, and cecal signet ring carcinoma) fixed with formalin and 5 proprietary fixatives advertised as formalin replacements.

  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Pathol Lab Med. 2006 Jan;130(1):13-4 [16390230.001]
  • (PMID = 15794674.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fixatives; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


69. Sebban S, Davidson B, Reich R: Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch; 2009 Jan;454(1):71-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed the expression of LOXL2, LOXL3, and LOXL4 in cancers involving the serosal cavities-breast carcinoma, ovarian carcinoma, and malignant mesothelioma using reverse-transcriptase polymerase chain reaction.
  • In malignant mesothelioma, LOXL4 and its splice variants were expressed at all sites.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Exons / genetics. Female. Humans. Middle Aged. RNA, Neoplasm / genetics. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] J Cell Biochem. 2003 Mar 1;88(4):660-72 [12577300.001]
  • [Cites] Acta Cytol. 1994 Nov-Dec;38(6):945-52 [7992584.001]
  • [Cites] J Mol Histol. 2004 Nov;35(8-9):845-55 [15609098.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):18-25 [11836665.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1657-66 [12670920.001]
  • [Cites] J Biol Chem. 2001 Dec 28;276(52):48944-9 [11684696.001]
  • [Cites] EMBO J. 2005 Oct 5;24(19):3446-58 [16096638.001]
  • [Cites] Respiration. 1998;65(2):108-13 [9580921.001]
  • [Cites] Biochem J. 2001 Apr 15;355(Pt 2):381-7 [11284725.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Eur J Surg Oncol. 1994 Feb;20(1):33-6 [8131866.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1606-13 [9501082.001]
  • [Cites] Mol Cell Biochem. 1999 Apr;194(1-2):79-91 [10391127.001]
  • [Cites] Nat Struct Biol. 1999 Mar;6(3):228-32 [10074941.001]
  • [Cites] Biochim Biophys Acta. 2003 Apr 11;1647(1-2):220-4 [12686136.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2585-91 [12894545.001]
  • [Cites] Nat Genet. 2004 Feb;36(2):178-82 [14745449.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29226-32 [11323426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12817-22 [9371758.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;70:1-32 [11642359.001]
  • [Cites] Matrix Biol. 1995 Dec;14(9):727-31 [8785587.001]
  • [Cites] Semin Oncol. 1985 Mar;12(1):54-75 [2579439.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2068-75 [11066047.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11429-36 [16357151.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1377-87 [8620412.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jul;46(7):644-55 [17394133.001]
  • [Cites] Exp Cell Res. 1987 Nov;173(1):174-82 [2890532.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4478-83 [12154058.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1405-12 [11684957.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4123-9 [17456585.001]
  • (PMID = 19015874.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.4.- / Amino Acid Oxidoreductases; EC 1.4.3.- / LOXL2 protein, human; EC 1.4.3.- / LOXL3 protein, human; EC 1.4.3.- / LOXL4 protein, human
  •  go-up   go-down


70. Dvalishvili I, Charkviani L, Turashvili G, Burkadze G: The expression of cadherin e and clinical prognostic factors in uterine endometrioid adenocarcinoma. Georgian Med News; 2005 Nov;(128):17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of cadherin e and clinical prognostic factors in uterine endometrioid adenocarcinoma.
  • The aim of our study was to evaluate the association between the expression of E-cadherin and clinical prognostic factors in uterine endometrioid adenocarcinoma of different histological grade.
  • We have studied 104 postmenopausal women with diagnosis of endometrioid adenocarcinoma.
  • Histological study by hematoxylin-eosin has showed grade 1 endometrioid carcinoma in 35 cases (33.7%, group I), grade 2 adenocarcinoma in 44 cases (42.3%, group II), and grade 3 adenocarcinoma in 25 cases (24%, group III).
  • Our results suggest that the loss of E-cadherin expression is associated with a higher histological grade of uterine endometrioid adenocarcinoma, depth of myometrial invasion, lymph node positivity, coexistence of obesity and vaginal bleeding.
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Endometrioid / metabolism. Uterine Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16369055.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


71. Li HW, Leung SW, Chan CS, Yu MM, Wong YF: Expression of maspin in endometrioid adenocarcinoma of endometrium. Oncol Rep; 2007 Feb;17(2):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of maspin in endometrioid adenocarcinoma of endometrium.
  • Maspin is a member of the serpin family, whose expression is altered in neoplasia and malignancies of many tissues.
  • This study aimed at demonstrating the expression of maspin in human endometrial tissue and searching for any altered expression in endometrioid adenocarcinoma of the endometrium compared to normal endometrium.
  • The expression level of the maspin gene was studied using reverse transcriptase-polymerase chain reaction (RT-PCR) performed on RNA extracted from 34 endometrial cancer samples (including 24 with FIGO stage I disease and 10 with FIGO stage III disease) and 28 normal endometrium in proliferative or secretory phases.
  • Our results suggested that there is up-regulated expression of maspin in endometrioid endometrial adenocarcinoma.
  • It may play a role in the malignant transformation of human endometrial tissue.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Gene Expression Regulation, Neoplastic. Serpins / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


72. Watanabe J, Watanabe K, Jobo T, Kamata Y, Kawaguchi M, Imai M, Okayasu I, Kuramoto H: Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:452-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.
  • We reported that p27 induced by medroxyprogesterone acetate (MPA) may be involved in the progestin-induced growth suppression of human endometrial adenocarcinoma cells.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / drug therapy. Endometrial Neoplasms / drug therapy. Proliferating Cell Nuclear Antigen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515645.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Proliferating Cell Nuclear Antigen; 0 / p27 antigen; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


73. Reichert RA: The endocervical origin of HPV-positive mucinous/endometrioid ovarian tumors remains unproven. Int J Gynecol Pathol; 2010 May;29(3):298-300; author reply 300-1; discussion 300-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endocervical origin of HPV-positive mucinous/endometrioid ovarian tumors remains unproven.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Human papillomavirus 16 / growth & development. Ovarian Neoplasms / pathology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology


74. Uzan C, Darai E, Valent A, Graesslin O, Cortez A, Rouzier R, Vielh P: Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma. Virchows Arch; 2009 May;454(5):525-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma.
  • A role for the EGF system, in particular HER1 and 2, in growth of the endometrium has been suggested but HER1 and 2 have not been studied in all locations of endometriosis and in ovarian endometrioid adenocarcinoma (OEC) which is a rare form of malignant transformation of endometriosis.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Endometriosis / metabolism. Intestinal Diseases / metabolism. Ovarian Neoplasms / metabolism. Peritoneal Diseases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism


75. Ragni N, Ferrero S, Prefumo F, Muschiato B, Gorlero F, Gualco M, Fulcheri E: The association between p53 expression, stage and histological features in endometrial cancer. Eur J Obstet Gynecol Reprod Biol; 2005 Nov 1;123(1):111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Uterine papillary serous adenocarcinomas showed significantly higher p53 overexpression than uterine endometrioid adenocarcinomas (100.0% versus 61.0%, p<0.005).
  • p53 overexpression was significantly higher in the secretory variant (85.7%) than in the typical endometrioid carcinoma (60.0%) (p<0.05).
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894417.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


76. Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R: Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol; 2010 Oct;116(4):876-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One woman's biopsy sample demonstrated endometrioid adenocarcinoma, grade 2, but the lack of an evaluable screening biopsy sample makes it uncertain whether the carcinoma was preexisting.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20859151.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00108849/ NCT00431132
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Vaginal Creams, Foams, and Jellies; 4TI98Z838E / Estradiol
  •  go-up   go-down


77. Albores-Saavedra J, Martinez-Benitez B, Luevano E: Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol; 2008 Jul;27(3):333-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 2 small cell carcinomas of the endometrium arose from and were confined to endometrial polyps, one of which also showed foci of endometrioid adenocarcinoma.
  • All patients are alive and disease-free from 9 months to 7 years after treatment (mean survival, 47 months).
  • Our findings suggest that stage of disease and a polypoid gross feature are the best predictors for outcome in small cell carcinomas and large cell neuroendocrine carcinomas of the uterus.


78. Stewart SL, Wike JM, Foster SL, Michaud F: The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol; 2007 Dec;107(3):392-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority (88%) of PFTCs were adenocarcinomas; serous adenocarcinomas accounted for 44% and endometrioid adenocarcinomas for 19% of adenocarcinoma diagnoses.
  • Essentially half (49.9%) of PFTCs were poorly differentiated; 89% were unilateral at diagnosis.
  • Stage at diagnosis was fairly evenly distributed among localized (36%), regional (30%), and distant (32%).
  • Although the demographic characteristics of PFTC are similar to those of ovarian cancer, stage at diagnosis and the stable trend observed in PFTC are in contrast to ovarian cancer.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Female. Humans. Incidence. Infant. Middle Aged. Neoplasm Staging. Registries. United States / epidemiology

  • Genetic Alliance. consumer health - Fallopian Tube Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Dec;107(3):386-7 [18053873.001]
  • (PMID = 17961642.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


79. Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED, Silva EG, Deavers MT: Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol; 2008 Apr;21(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid transcription factor-1 (TTF-1) protein expression is widely used in the diagnosis of lung and thyroid carcinomas.
  • Tissue microarrays of 138 ovarian serous carcinomas, 65 endometrioid adenocarcinomas, 35 mucinous adenocarcinomas, 30 mucinous neoplasms of low malignant potential, and 10 clear cell carcinomas were stained with anti-TTF1-antibody.
  • In addition, whole tissue sections of 19 serous carcinomas, 5 endometrioid adenocarcinomas, 7 mucinous adenocarcinomas, and 3 clear cell carcinomas were stained.
  • In the tissue microarrays, TTF-1 nuclear expression was demonstrated in 2 of 65 (3%) of the endometrioid adenocarcinomas; no nuclear immunoreactivity was identified in the remaining ovarian neoplasms.
  • In the whole tissue sections, TTF-1 nuclear staining was present in 7 of 19 (37%) serous carcinomas, 1 of 5 (20%) endometrioid adenocarcinomas, and 1 of 3 (33%) clear cell carcinomas.
  • In most of the positive cases, staining was focal, but in one endometrioid adenocarcinoma in the tissue microarray and in one serous and one clear cell carcinoma in the whole tissue sections, there was diffuse positivity.
  • It should also be taken into consideration when evaluating adenocarcinomas involving the lung in patients with a history of a gynecologic malignancy.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. DNA-Binding Proteins / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246044.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / TTF1 protein, human
  •  go-up   go-down


80. Ozan H, Ozerkan K, Aker S, Bülbül M: A case with three primary tumors of the ovary, endometrium and gallbladder. Eur J Gynaecol Oncol; 2008;29(5):551-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology revealed a uterine endometrioid adenocarcinoma, a mucinous adenocarcinoma of the gallbladder, and an ovarian endometrioid carcinoma with a clear cell component.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Gallbladder Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051835.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Ioffe OB: Recent developments and selected diagnostic problems in carcinomas of the endometrium. Am J Clin Pathol; 2005 Dec;124 Suppl:S42-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These implications make the differential diagnosis between the 2 pathogenetic types, specifically their prototypes, endometrioid and serous endometrial carcinomas, paramount.
  • However, this differential diagnosis may be difficult owing to overlapping histologic features such as papillary architecture.
  • To that end, the differential diagnosis of endometrial tumors with papillary morphologic features is discussed in detail.
  • In addition, several recently described variants and histologic patterns of endometrial carcinoma that might present diagnostic problems, such as microglandular mucinous carcinoma, sertoliform carcinoma, carcinoma arising in an atypical polypoid adenomyoma, and endometrial carcinoma with a minimal deviation adenocarcinoma pattern of myoinvasion, are described.
  • [MeSH-major] Endometrial Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Biopsy. Cell Proliferation. Diagnosis, Differential. Endometrium / pathology. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468417.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


82. Numnum TM, Leath CA 3rd, Straughn MJ Jr: Synchronous primary endometrial and ovarian carcinoma in a patient with marantic endocarditis. Obstet Gynecol; 2006 Sep;108(3 Pt 2):748-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial evaluation revealed cardiac valvular disease, and the patient underwent aortic valve replacement.
  • This case is unusual in that the diagnosis of nonbacterial thrombotic endocarditis led to the diagnosis of a gynecologic malignancy.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Antineoplastic Agents / therapeutic use. Aortic Valve. CA-125 Antigen / blood. Carcinoma, Endometrioid / complications. Carcinoma, Endometrioid / diagnosis. Carcinoma, Endometrioid / therapy. Chest Pain. Combined Modality Therapy. Fallopian Tubes / surgery. Fatigue. Female. Heart Valve Diseases / surgery. Heart Valve Prosthesis. Humans. Hysterectomy. Omentum / surgery. Ovariectomy. Radiotherapy

  • Genetic Alliance. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018489.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen
  •  go-up   go-down


83. Hu YQ, Liu YJ: [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances]. Ai Zheng; 2005 Jan;24(1):104-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expressions of Cx43 and Skp2 were examined by immunohistochemistry in 81 specimens of epithelial ovarian tumor (13 specimens of adenoma, 12 specimens of borderline adenoma, and 56 specimens of adenocarcinoma).
  • RESULTS: Positive rates of Cx43 in ovarian adenoma, borderline adenoma, and ovarian adenocarcinoma were 84.6% (11/13), 66.7% (8/12), and 33.9% (19/56), respectivelyu expression level of Cx43 in ovarian adenocarcinoma was significantly lower than those in ovarian adenoma (P<0.01), and borderline adenoma (P<0.01).
  • Positive rates of Skp2 in ovarian adenoma, borderline adenoma, and ovarian adenocarcinoma were 0, 0, and 46.3% (26/56), respectivelyu expression level of Skp2 in ovarian adenocarcinoma was significantly higher than those in ovarian adenoma (P<0.01), and borderline adenoma (P<0.01).
  • Moreover, the expression levels of Cx43 and Skp2 were independent of age and histological type, but significantly associated with pathologic grade, clinical stage, and positive lymph node metastasis of ovarian adenocarcinoma.
  • Besides, in ovarian adenocarcinoma, expression level of Cx43 was moderately inversely correlated with that of Skp2 (r=-0.48, P<0.01).
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642212.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Connexin 43; 0 / S-Phase Kinase-Associated Proteins
  •  go-up   go-down


84. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med; 2005 Jan;11(1):63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.
  • Endometrioid ovarian carcinomas are frequently associated with endometriosis, but the mechanism for this association remains unknown.
  • Here we present the first genetic models of peritoneal endometriosis and endometrioid ovarian adenocarcinoma in mice, both based on the activation of an oncogenic K-ras allele.
  • In addition, we find that expression of oncogenic K-ras or conditional Pten deletion within the ovarian surface epithelium gives rise to preneoplastic ovarian lesions with an endometrioid glandular morphology.
  • Furthermore, the combination of the two mutations in the ovary leads to the induction of invasive and widely metastatic endometrioid ovarian adenocarcinomas with complete penetrance and a disease latency of only 7 weeks.
  • The ovarian cancer model described in this study recapitulates the specific tumor histomorphology and metastatic potential of the human disease.
  • [MeSH-major] Disease Models, Animal. Endometriosis / genetics. Ovarian Neoplasms / genetics. Protein Tyrosine Phosphatases / genetics. Tumor Suppressor Proteins / genetics. ras Proteins / genetics


85. Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC, Australian Cancer Study Group, Australian Ovarian Cancer Study Group: Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer; 2008 Nov;44(16):2477-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors.
  • Endometrioid and clear cell subtypes of ovarian cancer are both known to be closely associated with endometriosis and endometrial pathology, and so have often been combined in studies of causation.
  • We have examined these ovarian cancers separately for potentially distinct risk factors in our population-based, Australia-wide case control study of 142 women with incident invasive endometrioid, 90 with clear cell ovarian cancers and 1508 population controls.
  • Breast feeding and tubal ligation were also inversely associated, but significantly so only for the endometrioid subtype.
  • As expected endometriosis increased the risk of both subtypes (OR 2.2, 95% CI 1.2-3.9 for endometrioid and OR 3.0, 95% CI 1.5-5.9 for clear cell).
  • Endometrioid and clear cell ovarian cancers have some shared as well as some distinct risk factors, and therefore should be considered separately in studies of ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / epidemiology. Carcinoma, Endometrioid / epidemiology. Endometrial Neoplasms / epidemiology. Ovarian Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707869.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Investigator] Bowtell D; Chenevix-Trench G; Green A; Webb P; deFazio A; Gertig D; Traficante N; Moore S; Hung J; Fereday S; Harrap K; Sadkowsky T; Mellon A; Robertson R; Vanden Bergh T; Maidens J; Nattress K; Chiew YE; Stenlake A; Sullivan H; Alexander B; Ashover P; Brown S; Corrish T; Green L; Jackman L; Martin K; Ranieri B; White J; Jayde V; Bowes L; Mamers P; Schmidt T; Shirley H; Viduka S; Tran H; Bilic S; Glavinas L; Proietto A; Braye S; Otton G; Bonaventura T; Stewart J; Friedlander M; Bell D; Baron-Hay S; Ferrier A; Gard G; Nevell D; Young B; Camaris C; Crouch R; Edwards L; Hacker N; Marsden D; Robertson G; Beale P; Beith J; Carter J; Dalrymple C; Hamilton A; Houghton R; Russell P; Brand A; Jaworski R; Harnett P; Wain G; Crandon A; Cummings M; Horwood K; Obermair A; Wyld D; Nicklin J; Papadimos D; Perrin L; Ward B; Davy M; Hall C; Dodd T; Healy T; Pittman K; Oehler M; Henderson D; Hyde S; Miller J; Pierdes J; Blomfield P; Challis D; McIntosh R; Parker A; Brown B; Rome R; Allen D; Grant P; Hyde S; Laurie R; Robbie M; Healy D; Jobling T; Maniolitas T; McNealage J; Rogers P; Susil B; Veitch A; Constable J; Tong SP; Robinson I; Simpson I; Phillips K; Rischin D; Waring P; Loughrey M; O'Callaghan N; Murray B; Billson V; Galloway S; Pyman J; Quinn M; Hammond I; McCartney A; Leung Y; Haviv I; Purdie D; Whiteman D; Zeps N; Green AC; Parsons PG; Hayward NK; Webb PM; Purdie DM; Whiteman DC
  •  go-up   go-down


86. Pulay T, Baki M, Bodoky G, Dank M, Cseh J, Csejtei A, Csömör S, Erfán J, Esik O, Faluhelyi Z, Izsó J, Hernádi Z, Kammerer K, Magyar T, Mayer A, Megyery E, Moskovits K, Pécsi L, Pikó B, Pintér T, Ruzsa A, Szánthó A, Szántó I, Szántó J, Szucs M, Tálos Z, Thurzó L, Kásler M: [The results of ovarian cancer therapy in the Hungarian Centers in 2002-2003]. Orv Hetil; 2006 Dec 31;147(52):2493-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Authors presented data of treatment results and course of disease in 487 ovarian cancer patients treated by primary surgery and paclitaxel-carboplatin combination chemotherapy between July 1, 2002 and December 31, 2003.
  • Distribution of their histological diagnosis was as 69.6% serous, 10.7% mucinous, 5.1% endometrial and 4.7% undifferentiated carcinoma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / therapy. Adult. Aged. Brenner Tumor / therapy. Carboplatin / administration & dosage. Carcinoma, Endometrioid / therapy. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / therapy. Drug Administration Schedule. Female. Humans. Hungary / epidemiology. Middle Aged. Paclitaxel / administration & dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294573.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


87. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, Broaddus RR: Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol; 2008 Dec 20;26(36):5965-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The clinical records and pathology reports from women who underwent hysterectomy at our institution for endometrial or endocervical adenocarcinoma over an 11-year interval were reviewed.
  • Preoperative diagnosis of the LUS tumors more frequently included the possibility of endocervical adenocarcinoma.
  • Seventy-three percent of the LUS tumors had an immunohistochemical expression pattern typical of conventional endometrioid adenocarcinoma.

  • Genetic Alliance. consumer health - Lynch syndrome.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1984 Jun;63(6):825-32 [6728365.001]
  • [Cites] Obstet Gynecol. 1970 Jul;36(1):76-81 [4192878.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(1):26-35 [2707951.001]
  • [Cites] Hum Pathol. 1996 Feb;27(2):172-7 [8617459.001]
  • [Cites] Int J Gynecol Pathol. 1997 Jan;16(1):38-44 [8986531.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):117-21 [10425049.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4609-16 [15837969.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):87-94 [16323174.001]
  • [Cites] Can Assoc Radiol J. 2006 Feb;57(1):43-8 [16719212.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7810-7 [16885385.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2006 Dec;20(6):985-1000 [16895764.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):55-8 [17157904.001]
  • [Cites] N Engl J Med. 2007 Apr 26;356(17):1760-9 [17460231.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5158-64 [17925543.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Gynecol Oncol. 2001 Dec;83(3):513-7 [11733964.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2578-84 [11745192.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):998-1006 [12170086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5908-13 [12732731.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4364-70 [14645426.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):160-7 [15043304.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):439-44 [3378468.001]
  • (PMID = 19001318.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5T32 CA101642 02; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2645115
  •  go-up   go-down


88. Fambrini M, Bargelli G, Peruzzi E, Buccoliero AM, Pieralli A, Andersson KL, Scarselli G, Gallorini M, Zolfanelli F, Marchionni M: Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report. J Minim Invasive Gynecol; 2009 Sep-Oct;16(5):630-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Young women with polycystic ovary syndrome (PCOS) are at increased risk of endometrial adenocarcinoma (EAC) through chronic unopposed estrogen production.
  • We describe the first case, to our knowledge, of grade 1 endometrioid EAC arising in the context of complex atypical endometrial hyperplasia in a 26-year-old woman with thrombophilia and PCOS who wished to retain fertility potential and was treated using a levonorgestrel-releasing intrauterine system alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Contraceptive Agents, Female / administration & dosage. Endometrial Neoplasms / drug therapy. Intrauterine Devices. Levonorgestrel / administration & dosage

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. LEVONORGESTREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835809.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptive Agents, Female; 5W7SIA7YZW / Levonorgestrel
  •  go-up   go-down


89. Razorenova TS, Samsonova EA, Pozharisskiĭ KM, Razorenov GI: [Mathematical evaluation of prognostic significance of clinico-morphological and immunohistochemical features of endometrioid adenocarcinoma]. Vopr Onkol; 2007;53(6):682-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mathematical evaluation of prognostic significance of clinico-morphological and immunohistochemical features of endometrioid adenocarcinoma].
  • Complex examination was given to 76 patients with endometrioid adenocarcinoma and immunohistochemical parameters of estrogen and progesterone receptors, proliferative index (Ki-67), HER2 oncoprotein and clinico-morphological characteristics were entered into Excel database.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / chemistry. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / pathology
  • [MeSH-minor] Aged. Cell Differentiation. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Lymphatic Metastasis. Mathematical Computing. Menopause. Middle Aged. Models, Theoretical. Neoplasm Recurrence, Local / chemistry. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Prognosis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416138.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


90. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL: Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol; 2005 Mar;18(3):324-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis.
  • Endometrial intraepithelial neoplasia (also known as 'EIN') is a precursor to endometrioid endometrial adenocarcinoma characterized by monoclonal growth of mutated cells, a distinctive histopathologic appearance, and 45-fold elevated cancer risk.
  • Subjective application of criteria for diagnosis of EIN correlates well with objective morphometry and successfully segregates patients into high and low cancer risk subgroups with better reproducibility than atypical hyperplasia diagnosis.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] J Pathol. 2000 Mar;190(4):462-9 [10699996.001]
  • [Cites] Tidsskr Nor Laegeforen. 2000 Feb 10;120(4):496-9 [10833943.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):924-30 [10841828.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):697-703 [11041060.001]
  • [Cites] Int J Gynecol Pathol. 2000 Oct;19(4):301-9 [11109157.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):930-5 [11420465.001]
  • [Cites] Am J Obstet Gynecol. 2002 Apr;186(4):651-7 [11967486.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):326-31 [11986334.001]
  • [Cites] Histopathology. 1981 Nov;5(6):689-95 [7033100.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Pathol Annu. 1982;17 Pt 2:287-306 [7182754.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] J Pathol. 1988 Apr;154(4):335-41 [3385513.001]
  • [Cites] Pathol Res Pract. 1992 Oct;188(7):856-9 [1448376.001]
  • [Cites] Am J Obstet Gynecol. 1996 May;174(5):1518-21 [9065122.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:160-4 [8747391.001]
  • [Cites] Am J Surg Pathol. 1998 Aug;22(8):1012-9 [9706982.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1102-8 [10478671.001]
  • (PMID = 15529181.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092301-02; United States / NCI NIH HHS / CA / R01 CA092301; United States / NCI NIH HHS / CA / R01-CA92301; United States / NCI NIH HHS / CA / R01 CA092301-01A1; United States / NCI NIH HHS / CA / R01 CA092301-02; United States / NCI NIH HHS / CA / R01 CA092301-03; United States / NCI NIH HHS / CA / CA092301-03; United States / NCI NIH HHS / CA / CA092301-01A1
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS3054; NLM/ PMC2573865
  •  go-up   go-down


91. Smith SM, Hoffman MS: The role of vaginal hysterectomy in the treatment of endometrial cancer. Am J Obstet Gynecol; 2007 Aug;197(2):202.e1-6; discussion 202.e6-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The medical data were reviewed for medical comorbidities, preoperative and postoperative diagnosis, hospital course, surgical and postoperative complications, adjuvant treatments, and follow-up.
  • Medical comorbidities included hypertension (76.2%), cardiovascular disease (34.9%), diabetes mellitus (31.7%), and pulmonary disease (28.6%).
  • Of patients with intrauterine pathology, 89.5% had endometrioid adenocarcinoma.

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2009 Feb;200(2):e13-4 [18722577.001]
  • (PMID = 17689651.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Kobayashi H, Sumimoto K, Kitanaka T, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Terao T: Ovarian endometrioma--risks factors of ovarian cancer development. Eur J Obstet Gynecol Reprod Biol; 2008 Jun;138(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk increased with increasing age at ovarian endometrioma diagnosis.
  • We also analyzed whether the predisposition toward ovarian cancer is limited to endometrioid and clear cell carcinoma.
  • Clear cell carcinoma (39%) and endometrioid adenocarcinoma (35%) were commonly observed among women with ovarian cancer.
  • CONCLUSIONS: Some endometriosis lesions may predispose to clear cell and endometrioid ovarian cancers.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162283.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


93. Ohishi Y, Kaku T, Oya M, Kobayashi H, Wake N, Tsuneyoshi M: CD56 expression in ovarian granulosa cell tumors, and its diagnostic utility and pitfalls. Gynecol Oncol; 2007 Oct;107(1):30-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian tumors comprised 32 granulosa cell tumors, 3 Sertoli-stromal cell tumors, 14 fibrothecomas, 6 carcinoid tumors, 1 large cell neuroendocrine carcinoma, 17 endometrioid adenocarcinomas and 9 poorly differentiated serous adenocarcinomas.
  • RESULTS: All of the 32 granulosa cell tumors, all of the 3 Sertoli-stromal cell tumors, all of the 4 small cell carcinomas, 1 of 1 large cell neuroendocrine carcinoma, 11 of 14 fibrothecomas, 5 of 6 carcinoid tumors, 17 of 22 endometrial stromal sarcomas and 7 of 9 poorly differentiated serous adenocarcinomas were positive for CD56.
  • No immunoreactive cells were observed in 17 endometrioid adenocarcinomas or 47 ovarian follicles.
  • CD56 is useful in distinguishing between granulosa cell tumor and normal ovarian follicles or endometrioid adenocarcinoma.
  • Appropriate and cautious interpretation of CD56 expression should lead to a more accurate diagnosis of granulosa cell tumor.
  • [MeSH-major] Antigens, CD56 / analysis. Granulosa Cell Tumor / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583777.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
  •  go-up   go-down


94. Dilek S, Dilek U, Dede M, Deveci MS, Yenen MC: The role of omentectomy and appendectomy during the surgical staging of clinical stage I endometrial cancer. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):795-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Assessment of extrauterine spread is the most important objective of surgical staging in the endometrioid adenocarcinoma of uterine corpus.
  • In this study, our objective was to determine whether omentectomy and appendectomy should be a part of the surgical staging in endometrioid adenocarcinoma of uterine corpus.
  • Fifty-one patients who were diagnosed as clinical stage I endometrioid adenocarcinoma of corpus uteri were reviewed.
  • [MeSH-major] Adenocarcinoma / pathology. Appendectomy. Endometrial Neoplasms / pathology. Omentum / surgery. Peritoneal Cavity / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681763.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Cossu A, Budroni M, Capobianco G, Pirino D, Palmieri G, Dessole S, Tanda F, Cesaraccio R, Cherchi PL: Epidemiological aspects of ovarian malignancies in North Sardinia in the period 1992-2001. Eur J Gynaecol Oncol; 2005;26(1):47-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant ovarian tumors have been continuously increasing in Western countries and represent the leading cause of death for gynecological cancer.
  • In fact, the mortality for malignant ovarian tumors remains very high with a low percentage of 5-year survival in the advanced stage of disease.
  • The aim of this study was to evaluate the incidence trend and epidemiological characteristics of malignant ovarian tumors in the Province of Sassari, Sardinia (Italy) in the period 1992-2001 and to report the variations in comparison to the 1974-1985 period.
  • The analysis of our data regarding the period 1992-2001, if compared with those of the period 1974-85, showed an increase of malignant ovarian tumors which triplicated achieving an incidence of 11.99/100,000 vs 4.27/100,000.
  • The analysis of our epidemiologic data showed an increase of the age of first diagnosis (mean 60.9 years for epithelial ovarian tumors), the occurrence of the cancer in women at low socio-economic levels and a family history of cancer among the patients with malignant ovarian tumors.
  • [MeSH-minor] Adenocarcinoma, Mucinous / epidemiology. Adenocarcinoma, Mucinous / etiology. Adenocarcinoma, Mucinous / mortality. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Endometrioid / epidemiology. Carcinoma, Endometrioid / etiology. Carcinoma, Endometrioid / mortality. Cystadenocarcinoma, Serous / epidemiology. Cystadenocarcinoma, Serous / etiology. Cystadenocarcinoma, Serous / mortality. Female. Humans. Incidence. Italy / epidemiology. Middle Aged. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755000.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down






Advertisement